Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.163
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
2020English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy